Increased ARF6 activation correlates with HGF stimulation in non-invasive prostate cancer cells

Abstract

Aim: The effects of hepatocyte growth factor (HGF) on a non-invasive prostate cancer cell line (CAHPV-10), expressing cMET were studied, to mimic the possible effects neo-adjuvant androgen deprivation therapy may have in promoting tumour progression.

Methods: Prostate epithelial cells and prostate cancer cells derived from cancer metastatic sites were analysed using cell culture assays, immunofluorescence, quantitative real-time polymerase chain reaction and western blotting, with or without HGF stimulation.

Results: HGF significantly enhanced cell proliferation and induced cell scattering and invasion in CAHPV-10 cells compared to untreated controls. Active adenosine diphosphate-ribosylation factor 6 (ARF6) was found to be present in all metastatic prostate cancer cells, with levels highest in the most aggressive cell line, PC-3. Following stimulation with HGF, active ARF6 expression was substantially elevated in CAHPV-10 cells.

Conclusion: These findings provide further molecular insight into the progression of prostate cancer and highlights potential issues for early prostate cancer therapeutic strategies.

Keywords

Prostate cancer / adenosine diphosphate-ribosylation factor 6 / hepatocyte growth factor stimulation / androgen deprivation therapy

References

[1] Anonymous. Cancer Research UK [Internet]. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence. [Last accessed on 14 Aug 2017]

[2] Payne H.Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments.Br J Cancer2011;105:1628-34 PMCID:PMC3242586

[3] Shelley MD,Coles B,Staffurth J.A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma.Cancer Treat Rev2009;35:9-17

[4] Heidenreich A,Bolla M,Matveev VB,Zattoni F.EAU guidelines on prostate cancer.Eur Urol2008;53:68-80

[5] Humphrey PA,Zarnegar R,Ratliff TL,Day ML.Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.Am J Pathol1995;147:386-96 PMCID:PMC1869824

[6] Tsuka H,Li B,Matsukawa S.Enhanced hepatocyte growth factor level in human prostate cancer treated with endocrine therapy.Int J Oncol1998;13:169-76

[7] Maeda A,Hara S,Miwa Y,Yokoyama M,Oyasu R.Inactivation of AR activates HGF/c-Met system in human prostatic carcinoma cells.Biochem Biophys Res Commun2006;347:1158-65

[8] Verras M,Xue H,Wang Y.The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression.Cancer Res2007;67:967-75

[9] Nishimura K,Takada S,Tsujimura A,Miki T,Okuyama A.Regulation of invasive potential of human prostate cancer cell lines by hepatocyte growth factor.Int J Urol1998;5:276-81

[10] Takahashi M,Shimada T,Kawabe T,Matsumura M,Terano A,et al.Hepatocyte growth factor is the most potent endogenous stimulant of rabbit gastric epithelial cell proliferation and migration in primary culture.J Clin Invest1995;95:1994-2003 PMCID:PMC295775

[11] Dignass AU,Podolsky DK.Hepatocyte growth factor/scatter factor modulates intestinal epithelial cell proliferation and migration.Biochem Biophys Res Commun1994;202:701-9

[12] Jeffers M,Vande Woude GF.Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network.Mol Cell Biol1996;16:1115-25 PMCID:PMC231094

[13] Weidner KM,Naldini L,Sachs M,Rieder H.Molecular characteristics of HGF-SF and its role in cell motility and invasion.EXS1993;65:311-28

[14] Silvagno F,Arese M,Giraudo E,Camussi G,Bussolino F.In vivo activation of met tyrosine kinase by heterodimeric hepatocyte growth factor molecule promotes angiogenesis.Arterioscler Thromb Vasc Biol1995;15:1857-65

[15] Gupta A,Roehrborn CG,Zlotta AR.Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer.Clin Cancer Res2008;14:7385-90

[16] Nagakawa O,Fujiuchi Y,Akashi T,Fuse H.Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer.Eur Urol2005;48:686-90

[17] Naughton M,Zhu X,Vollmer RT.Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer.J Urol2001;165:1325-8

[18] Tsuka H,Li B,Matsukawa S.Expression of c-MET/HGF receptor mRNA and protein in human non-malignant and malignant prostate tissues.Int J Oncol1998;13:927-34

[19] van Leenders G,Aalders T,Ruiter D.Intermediate cells in normal and malignant prostate epithelium express c-MET: implications for prostate cancer invasion.Prostate2002;51:98-107

[20] Pisters LL,Zhau HE,von Eschenbach AC.c-met proto-oncogene expression in benign and malignant human prostate tissues.J Urol1995;154:293-8

[21] Miura H,Tsujimura A,Matsumoto K,Okuyama A.Effects of hepatocyte growth factor on E-cadherin-mediated cell-cell adhesion in DU145 prostate cancer cells.Urology2001;58:1064-9

[22] Sanders AJ,Mason MD.Suppression of hepatocyte growth factor activator inhibitor-1 leads to a more aggressive phenotype of prostate cancer cells in vitro.Int J Mol Med2007;20:613-9

[23] Wells CM,Masters JR.Rho family GTPases are activated during HGF-stimulated prostate cancer-cell scattering.Cell Motil Cytoskeleton2005;62:180-94

[24] Yue D,Ma P,Chen H,Ren CS.Effects of transferred NK4 gene on proliferation, migration, invasion and apoptosis of human prostate cancer DU145 cells.Asian J Androl2010;12:381-9 PMCID:PMC3739269

[25] Davies G,Mason MD.Cell-cell adhesion molecules and signaling intermediates and their role in the invasive potential of prostate cancer cells.J Urol2000;163:985-92

[26] Palacios F,Schweitzer J,D'Souza-Schorey C.An essential role for ARF6-regulated membrane traffic in adherens junction turnover and epithelial cell migration.EMBO J2001;20:4973-86 PMCID:PMC125602

[27] Hongu T,Fukuhara S,Sakimoto S,Ema M,Itoh S,Hasegawa H,Kanaho Y.Arf6 regulates tumour angiogenesis and growth through HGF-induced endothelial β1 integrin recycling.Nat Commun2015;6:7925

[28] Tague SE,D'Souza-Schorey C.ADP-ribosylation factor 6 regulates tumor cell invasion through the activation of the MEK/ERK signaling pathway.Proc Natl Acad Sci U S A2004;101:9671-6 PMCID:PMC470733

[29] Muralidharan-Chari V,Clancy J,Suckow MA,Castellino FJ,D'Souza-Schorey C.ADP-ribosylation factor 6 regulates tumorigenic and invasive properties in vivo.Cancer Res2009;69:2201-9 PMCID:PMC3761373

[30] Hashimoto S,Hashimoto A,Hamaguchi M,Sabe H.Requirement for Arf6 in breast cancer invasive activities.Proc Natl Acad Sci U S A2004;101:6647-52 PMCID:PMC404099

[31] Morgan C,Hopkins L,Kynaston H.Increased expression of ARF GTPases in prostate cancer tissue.Springerplus2015;4:342 PMCID:PMC4499334

[32] Morgan C,Kynaston HG.The role of adhesion molecules as biomarkers for the aggressive prostate cancer phenotype.PLoS One2013;8:e81666 PMCID:PMC3864842

[33] Stephens P,Cook H,Zhiquiang W.Phenotypic variation in the production of bioactive hepatocyte growth factor/scatter factor by oral mucosal and skin fibroblasts.Wound Repair Regen2001;9:34-43

[34] Tate A,Bradley MJ,Davis R,Edlund M.Met-Independent Hepatocyte Growth Factor-mediated regulation of cell adhesion in human prostate cancer cells.BMC Cancer2006;6:197 PMCID:PMC1559714

[35] Stoker M,Perryman M.Scatter factor is a fibroblast-derived modulator of epithelial cell mobility.Nature1987;327:239-42

[36] Pasdar M,Marreli M,Park M.Inhibition of junction assembly in cultured epithelial cells by hepatocyte growth factor/scatter factor is concomitant with increased stability and altered phosphorylation of the soluble junctional molecules.Cell Growth Differ1997;8:451-62

[37] Hiscox S.Association of the HGF/SF receptor, c-met, with the cell-surface adhesion molecule, E-cadherin, and catenins in human tumor cells.Biochem Biophys Res Commun1999;261:406-11

[38] Herrera R.Modulation of hepatocyte growth factor-induced scattering of HT29 colon carcinoma cells.Involvement of the MAPK pathway. J Cell Sci1998;111:1039-49

[39] Potempa S.Activation of both MAP kinase and phosphatidylinositide 3-kinase by ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly.Mol Biol Cell1998;9:2185-200 PMCID:PMC25472

[40] Dai Y.BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.Mol Cancer Ther2010;9:1554-61

[41] Fujiuchi Y,Murakami K,Saiki I.Effect of hepatocyte growth factor on invasion of prostate cancer cell lines.Oncol Rep2003;10:1001-6

[42] Davies G,Mason MD.Targeting the HGF/SF receptor c-met using a hammerhead ribozyme transgene reduces in vitro invasion and migration in prostate cancer cells.Prostate2004;60:317-24

[43] Maitland NJ.Getting closer to prostate cancer in patients - what scientists should want from clinicians.J Cancer Metastasis Treat2017;3:262-70

[44] Kondo A,Yano H,Mazaki Y.A new paxillin-binding protein, PAG3/Papalpha/KIAA0400, bearing an ADP-ribosylation factor GTPase-activating protein activity, is involved in paxillin recruitment to focal adhesions and cell migration.Mol Biol Cell2000;11:1315-27 PMCID:PMC14849

[45] Li M,Ng SS,He ML,Lai L,Chen Y,Kung HF.Adenosine diphosphate-ribosylation factor 6 is required for epidermal growth factor-induced glioblastoma cell proliferation.Cancer2009;115:4959-72

[46] Gaschet J.Distribution of ARF6 between membrane and cytosol is regulated by its GTPase cycle.J Biol Chem1999;274:20040-5